DDInter1382 DDInter927
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Palonosetron {u} (Compound) resembles {v} (Compound) Praziquantel
Palonosetron {u} (Compound) binds {v} (Gene) HTR3A
Palonosetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Palonosetron {u} (Compound) causes {v} (Side Effect) Malnutrition
Palonosetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ezogabine
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Palonosetron {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Palonosetron {u} may lead to a major life threatening interaction when taken with {v} Mirtazapine
Palonosetron (Compound) resembles Praziquantel (Compound)
Palonosetron (Compound) binds HTR3A (Gene)
Palonosetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Palonosetron (Compound) causes Malnutrition (Side Effect)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole
Palonosetron may lead to a major life threatening interaction when taken with Lefamulin
Palonosetron may lead to a major life threatening interaction when taken with Mirtazapine